Ilinpru

Linagliptin, the active ingredient in Ilinpru, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used as part of a comprehensive diabetes treatment plan.

GNH USA supplies Ilinpru as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Ensuring timely delivery and regulatory compliance.

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycemic control when combined with diet, exercise and other antidiabetic agents. - Adults with renal impairment: offers effective glucose lowering without the need for dose adjustment. - Patients inadequately controlled on metformin: serves as an add‑on therapy to achieve target HbA1c. - Elderly patients: provides effective glycaemic control with a low risk of hypoglycaemia. - Combination therapy with insulin: can be added to basal insulin regimens to further lower HbA1c.

Linagliptin may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as nasal congestion or sore throat. - Headache: transient mild to moderate headache. - Nasopharyngitis: inflammation of the nasal passages and throat. - Diarrhoea: mild, self‑limiting episodes of loose stools.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain indicating possible pancreatic inflammation. - Severe hypersensitivity reactions: rash, angioedema or anaphylaxis. - Hepatic enzyme elevation: notable increase in liver transaminases. - Severe allergic reaction: Stevens‑Johnson syndrome presenting with skin detachment.

When prescribing linagliptin, several precautions should be considered to ensure safe use. - Renal function: monitor renal status, although dose adjustment is not required, use caution in severe impairment. - Hepatic impairment: assess liver function before initiation and periodically during therapy. - Pancreatitis history: avoid use in patients with a prior history of pancreatitis. - Concomitant hypoglycaemic agents: adjust doses of sulfonylureas or insulin to reduce risk of hypoglycaemia. - Cardiovascular disease: monitor for any worsening of heart failure symptoms. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Linagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin exposure; avoid co‑administration. - Strong CYP3A4 inducers: may reduce linagliptin levels, compromising glucose control.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia; monitor blood glucose. - Diuretics: may affect renal handling; observe renal function. - Rifampicin: may lower linagliptin concentrations; consider alternative therapy.